DREAMS — mazdutide in Chinese populations
The companion phase 3 programme to GLORY, evaluating mazdutide in Chinese adults across metabolic indications. The Institute reports the GLORY and DREAMS estimates separately because the enrolled populations differ in baseline body-mass index from the Western programmes.
The companion phase 3 programme to GLORY, evaluating mazdutide in Chinese adults across metabolic indications. The Institute reports the GLORY and DREAMS estimates separately because the enrolled populations differ in baseline body-mass index from the Western programmes.
Sponsor class: Manufacturer-sponsored. First record: 2022.
Records in this programme
Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.
| Record | Compound | Phase | Status | Design | Randomised | Year | Certainty |
|---|---|---|---|---|---|---|---|
| DREAMS-1 | Mazdutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 319 | 2024 | Moderate |
| DREAMS-2 | Mazdutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 731 | 2024 | Moderate |
| DREAMS-3 | Mazdutide | Phase 3 | Ongoing | Randomised, double-blind, active-controlled | — | — | Not rated |
| DREAMS-2-PKprogramme record | Mazdutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2024 | Very low |
| DREAMS-2-RENAL-IMPprogramme record | Mazdutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2024 | Very low |
| DREAMS-3-BODY-COMPprogramme record | Mazdutide | Phase 3 | Ongoing | Randomised, double-blind, placebo-controlled | — | — | Very low |
| DREAMS-3-REGIONAL-CNprogramme record | Mazdutide | Phase 3 | Ongoing | Randomised, double-blind, placebo-controlled | — | — | Very low |
| DREAMS-3-REGIONAL-JPprogramme record | Mazdutide | Phase 3 | Ongoing | Randomised, double-blind, placebo-controlled | — | — | Very low |